NCT01683188
Clinical Trial Detail
Contact
Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT01683188 |
| Title | HD IL-2 + Vemurafenib in Patients With BRAF Mutation Positive Metastatic Melanoma |
| Acronym | PROCLIVITY01 |
| Recruitment | Terminated |
| Gender | both |
| Phase | Phase III |
| Variant Requirements | Yes |
| Sponsors | Prometheus Laboratories |
| Indications | |
| Therapies | |
| Age Groups: | adult |
| Covered Countries | USA |
CKB BOOST